trial

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

NCTId NCT03978832
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 69 (actual)
Sponsored by Indivior Inc.
Primary completion 2020-05-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
69 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-06-28
Primary completion
2020-05-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Indivior Inc.Lead Sponsor

Investigators

1
David P Walling, PhDPrincipal Investigator

Sites

1 total
Garden Grove, United States

Facts & assertions

4 sourced
Enrollment
69
Phase
PHASE4
Primary Completion Date
2020-05-12
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Indivior Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
David P Walling, PhD
person